Member Info for GIVMESUNSHINE

Whoops - good spot Lincol - Didnt notice that - odd its was top of google when i typed in CIRT Test - anyway - worth repeating - many more case studies to add now

One interesting thing about the CURRENT execution plan for Cirt (and PSE in the Future) is how OBD are leveraging off the private sector to produce the case files nad information required for further reglatory submissions, such a NICEand FDA in the future. Jon has stated this in presentationand updates, "not quite there yet" was the feedback in may last year.. Its been made clear that the US adoption to No1 Target, Those case files should be building up nicely now.

Can you provide any examples of how this test is useful in managing treatment with ICIs?

Tom: Understanding a patient’s likely response to ICI therapy is a fundamental benefit of using CiRT to help guide treatment planning. But there are additional compelling benefits.

Recently, we ran CiRT on a young, 34-year-old woman diagnosed with late-stage colorectal cancer that had also metastasized to the liver. Her biopsy was PD-L1 negative, and her microsatellite instability (MSI) was low, which usually means she is not even considered for ICI therapy. However, the CiRT test indicated that she had a high probability of responding to ICIs. Based on this new information, her oncologist has recommended her a second-line treatment with ICIs.

In another case, a 90-year-old female patient with recurrent squamous cell carcinoma tested positive for PD-L1 protein by IHC. She had a tumor proportion score of 90 percent, which would generally warrant ICI treatment, yet her CiRT profile returned a low probability of response. When treated with the ICI, the patient did not respond – confirming our prediction.

These are not isolated cases. In some of the most widely treated cancers, more than one in six patients with a negative PD-L1 result are still likely to respond to ICI therapy if given a chance. This means that there is another major use opportunity where CiRT can significantly impact and potentially change anti-cancer care.

Very good read

https://www.precisionmedicineonline.com/companion-diagnostics/qa-how-noninvasive-blood-test-changing-immunotherapy-treatment

Hi Nick - The amount received in reimbursements is still an evolving story , from memory at last count it was going up slightly to about $2400 average. Jon Burrows appears to know his stuff and was deploying a strategy of bulk invoicing to speed up the process of more solid reimbursement and ease of payment. As we know Cirt sales trebled over the 6 months to 97 month in June - Growth stemming from the clinical steering groups .. My hope is to see approx. 200 test as of Dec 23 , there have been several for advisory groups and that would show OBD have a solid commercial plan. I think BUPA will not hit any significant numbers as yet, but will have an impact in 2024.. With regards PSE , I think the short to mid target is for PSE to be the back up test after a positive PSA.. There is huge potential here as it will bring medial and financial benefit to the consultant and insurers .. may be slow are fist , but this year will be very interesting on that from IMO GLA

It does look a very exicting pipeline - We just need to see seeds of recognition and growth shown in CIrt to continue to come through towards critical mass - first one is always the hardest , If we are anywhere near 200+ tests a day then its job done for OBD future and shareholder value..Loss making isnt an issue when sales are growing, they have spoke a good game for 3 years but meaningful revenue only started feb 2023 and took off strongly from there - 6 month is is a long time in this case.. Then you have PSE - 2024 will be a good year for PSE IMO

Hi Dug

Agree - 250 would be icing on the cake - its such an unknown and we have limited data to go on as its biggest rise by far was in june - the last update ! .. I learnt to my cost over the years to alway look to the mid low case on the AIM, but I share your hopes..Not a pipe dream at all . With regards to PSE.. Im sure alot will happen over the year, but not expecting anything of significance on results day

FYI - Anyone who hasnt watched the Jan 2022 Webinar should take the time to look back at the strategy that Jon explained to penetrate the Cirt into the US.. 6 months later and its was really starting to bear fruit .. now another 6 months have passed..

Hi Dug

Yes - Looking forwards to the webinar, financial results to Sept 2023 can be pretty much worked out from what we know. If we assume June 23 is last reconzised revenue for 2023 then I think H2 will give an estimate of £600-700k ish Revenue, + about £300k from grants and about £4.4-5m net cash outflow (including £900k tax credit (April23).

However thats backwards looking - June - Dec CIRTs are a big unkown - Im looking for 120- 150 month tests by end of September 2023 - Hopefully more, but thats what im happy with as would mean we kicked off the year with about $400k month revenue at a big margin - almost everying on revenue will no drop on to the bottom line

Happy New Year

Nice Blog about the growth potential in PSA Testing - The article mentions PSE test as a risk /competition to PSA Market , however fails to grasp that its now avaiable and is by OBD. I think he needs to do a bit more research :)

"In February 2023, University of East Anglia’ researchers created a revolutionary blood test that can diagnose prostate cancer more precisely than existing methods. According to the research, the blood test called Prostate Screening Episwitch (PSE)’s accuracy is 94% more than the current methods in use".

https://www.fmiblog.com/2024/01/02/global-prostate-specific-antigen-testing-industry-is-anticipated-to-expand-at-a-12-0-cagr-until-2033-as-per-fmis-projections/

At last count we had 1 clinical advisory board set up in NYC.. hopefully more by now

Hi 5085

Glad ive logged on to see that, thats great news .. That might warrant an RNS

With worked orders it's impossible to tell - the time printed has nothing to do with the time executed or placed - it's "worked" throughout the day. I cannot see all that volume from the results date announcement alone - doesn't make much sense - from my take we had a big movement because there was a large buy order to fill and the was selling into the rise that filled it .. at least it has lifted the boredom

I take back what i said earlier - it would seem we have a buyer working orders in the background .. far to many roundnumber trades /delayed.. plus we did a a few earlier in the week

AIM is a very odd place - Why on hells earth would you pay nearly 32p today if you wasnt willing to by at 27p 2 day ago - I t does go to show how much hot money goes in and out of AIM shares - Not complianing - I feel much better floating above 30p. just bemused

Morning - Its all about Cirt for me.. The company has stated that they dont add yet to be paid tests as recievables and they bulk invoice ffor insurance claims therefore I dont expect 2023 numbers to be huge. Can pretty much works it out on a mid case of say about june being the last month to make it into the accounts.. FY 2023 Rev will be about £700k Ish IMO, but that not the important thing as june alone would be £250k.. its the current grow from June that im looking for.

Nice little find Dug

Trades have woken up today - over 550k volume so far

Its been an odd few weeks for OBD voulme and share price. OBD presented for Jeffries Investments 15th -16th November and the SP rallied on a flurry of buys, over the nevt few weeks volume rose and it seem to push down relentlessly..Now volume has dissapeared and floating around this level for a few sessions now..

Having witnessed many a AIM co'sBIO raise funds in the past, the recent movements suggest to me that OBD may well have got a placing away around the 28-30p level.. Obviously cant tell, but just seen these types of movements before (espsially after prsenting at Institutional Investment seminars) , I hope they have as it would remove the one nagging doubt and shore up the SP more than any dilution. Just an enquiring thought

UK Lab cannot be far from certification, I think the company stated uk lab early 2024 , so prepping for the now